ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

Description

Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.

Conditions

Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.

Physiological Changes Underlying the Weight Loss Plateau in Human

ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Seattle

Fred Hutch Cancer Center, Seattle, Washington, United States, 98109

Seattle

University of Washington - South Lake Union, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * BMI 30.0 - 50.0 kg/m2
  • * Able to attend study intervention classes and study visits/assessments
  • * Independently living with access to food preparation facilities
  • * Current smoker or regular use of nicotine containing products and/or cannabis
  • * Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use
  • * Known cognitive impairments or h/o stroke
  • * Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%))
  • * Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate
  • * Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding
  • * Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants
  • * History of bariatric surgery
  • * History of eating disorder
  • * Current participation in a formal weight loss program
  • * Prior or current participation in a research study involving weight loss
  • * Weight-reduced by \>10% within past year
  • * Weight \> 330 pounds (MRI limit)
  • * Allergy or intolerance to or unwillingness to consume study foods provided at visit
  • * MRI contraindication (e.g., implanted metal, claustrophobia)
  • * Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures
  • * Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

Ages Eligible for Study

18 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Washington,

Ellen Schur, MD, MS, PRINCIPAL_INVESTIGATOR, University of Washington

Marian Neuhouser, PhD, RD, PRINCIPAL_INVESTIGATOR, Fred Hutch Cancer Center

Jenny Tong, MD, PRINCIPAL_INVESTIGATOR, University of Washington/VA Puget Sound

Study Record Dates

2027-07-31